# Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis

> **NCT05866809** · PHASE2 · COMPLETED · sponsor: **CuromeBiosciences** · enrollment: 23 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** HK-660S
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05866809
- **Lead sponsor:** CuromeBiosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-07-24
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866809, "Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05866809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*